Domo signs strategic collaboration agreement with AWS for AI solutions
Meredith (NYSE:MDP) Cook, Senior Vice President, General Counsel & Secretary at ANI Pharmaceuticals (NASDAQ:ANIP), recently sold 400 shares of common stock, amounting to a total value of $25,332. The shares were sold at a price of $63.33 each. Following the transaction, Cook retains ownership of 80,545 shares in the company. This sale was executed under a Rule 10b5-1 trading plan, which Cook adopted on September 17, 2024. According to InvestingPro analysis, the company appears slightly undervalued based on its Fair Value metrics, with 5 analysts recently revising their earnings estimates upward. For detailed insights and more exclusive tips, check out the comprehensive Pro Research Report, available to InvestingPro subscribers.
In other recent news, ANI Pharmaceuticals has received approval from the U.S. Food and Drug Administration for an updated label for ILUVIEN, expanding its use to treat chronic non-infectious uveitis affecting the posterior segment of the eye. This development allows ANI to market ILUVIEN for this new indication in the U.S., adding to its existing approval for diabetic macular edema. Additionally, Jefferies has initiated coverage on ANI Pharmaceuticals with a Buy rating and a price target of $80, citing the company’s momentum in branded rare disease products and generics as key growth drivers. JPMorgan also began coverage with an Overweight rating and set a higher price target of $85, highlighting the potential growth from ANI’s strong portfolio, including the recently acquired Yutiq and Iluvien.
Truist Securities, however, maintained a Hold rating with a $62 target, noting the strategic consolidation of ANI’s Established Brands and the challenges faced by Iluvien and Yutiq in terms of reimbursement. Meanwhile, Leerink Partners raised its price target for ANI Pharmaceuticals to $82 from $80, following the company’s fourth-quarter financial results that exceeded expectations. Leerink emphasized the strong outlook for Cortrophin Gel and the anticipated growth of Iluvien/Yutiq as significant factors in ANI’s future performance. The company has also adjusted its 2025 revenue and EBITDA guidance upwards, reflecting confidence in its strategic direction. These developments indicate a period of significant activity and transition for ANI Pharmaceuticals, as it continues to evolve its product offerings and market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.